Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Harald Schweitzer"'
Autor:
Jian Shen, Jiping Yang, Winfried Heyse, Harald Schweitzer, Norbert Nagel, Doris Andert, Chengyue Zhu, Vincent Morrison, Gregory A. Nemeth, Teng-Man Chen, Zhicheng Zhao, Timothy A. Ayers, Yong-Mi Choi
Publikováno v:
Journal of Pharmaceutical Analysis, Vol 4, Iss 3, Pp 197-204 (2014)
Otamixaban is a potent (Ki=0.5Â nM) fXa inhibitor currently in late-stage clinical development at Sanofi for the management of acute coronary syndrome. Being unproductive in obtaining a suitable crystal of Otamixaban, the required enantiomeric chara
Externí odkaz:
https://doaj.org/article/e216df50786d432c972e05ee222dd331
Autor:
Jiping Yang, Jian Shen, Winfried Heyse, Doris Andert, Harald Schweitzer, Chengyue Zhu, Gregory A. Nemeth, Yong-Mi Choi, Zhicheng Zhao, Timothy A. Ayers, Vincent Morrison, Teng-Man Chen, Norbert Nagel
Publikováno v:
Journal of Pharmaceutical Analysis
Journal of Pharmaceutical Analysis, Vol 4, Iss 3, Pp 197-204 (2014)
Journal of Pharmaceutical Analysis, Vol 4, Iss 3, Pp 197-204 (2014)
Otamixaban is a potent (Ki=0.5Â nM) fXa inhibitor currently in late-stage clinical development at Sanofi for the management of acute coronary syndrome. Being unproductive in obtaining a suitable crystal of Otamixaban, the required enantiomeric chara
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::286fd0572070c3d598a63939b6535cd2
Autor:
Norbert Nagel, Harald Schweitzer, Hansjörg Urbach, Winfried Heyse, Barbara Müller, Harald Berchtold
Publikováno v:
Acta Crystallographica Section E Structure Reports Online. 57:o463-o465
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94feb57631d367c97ff9ee7f7b4c1869
https://doi.org/10.1107/s1600536801006948
https://doi.org/10.1107/s1600536801006948